Long-term follow-up of gene therapy for dry mouth
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows patients who previously received gene therapy for dry mouth caused by radiation. It aims to track long-term safety and any lasting benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received the gene therapy drug in an earlier study called MGT-AQP1-201.
- You must not have withdrawn your consent from that earlier study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
This trial tests a new type of treatment called circular RNA to see if it can help people with long-term dry mouth after radiation for head and neck cancer. It's for patients whose dry mouth hasn't gone away with other treatments.
This trial tests whether repeated injections of stem cells (mesenchymal stem cells) can help people who have chronic dry mouth after radiation therapy for head or neck cancer. The goal is to improve saliva production and reduce discomfort.
This trial tests a new treatment using special cells (mesenchymal stromal cells) from your own bone marrow to help with dry mouth that is not caused by radiation. The goal is to see if it can increase saliva production and improve quality of life.
This trial compares a new radiation technique designed to reduce dry mouth (xerostomia) with standard radiation for people with nasopharyngeal cancer. It aims to see if the new approach can protect saliva glands while still treating the cancer effectively.
This trial tests whether spermidine (a natural compound) can help prevent dry mouth caused by radiation treatment for head and neck cancer. It is for patients who will receive a significant dose of radiation to their saliva glands.
Hear when a new Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.